Arsenic and Retinoic Acid Therapies for Acute Myeloid Leukemia
This community focuses on the clinical management and molecular mechanisms of acute myeloid leukemia (AML), specifically the use of arsenic trioxide and retinoic acid to induce differentiation and apoptosis in malignant myeloid cells.
The research is dominated by studies on acute promyelocytic leukemia (APL) and broader AML subtypes, with a heavy emphasis on arsenic trioxide and all-trans retinoic acid as core therapeutic agents. Recurring themes include targeted therapy for relapsed or refractory cases, the role of signaling pathways in cell survival, and the application of stem cell transplantation. While the core is hematologic malignancy, the community also encompasses work on hepatocellular carcinoma and breast cancer, often examining shared mechanisms of apoptosis or targeted drug resistance. The literature frequently addresses clinical trial outcomes, risk stratification, and the development of novel inhibitors for specific genetic alterations in leukemia cells.
Arsenic research accounts for 3,525 papers within this group, representing 2.3% of all tracked arsenic research. Actinium research contributes 93 papers, making up 4.8% of that element's tracked literature.
The community comprises 9,188 papers, with the highest publication volume in Blood, Leukemia, and Oncotarget.
Recent work includes consensus updates on minimal residual disease in AML, pediatric diagnosis guidelines, and phase II trials for targeted therapies like quizartinib and revumenib in newly diagnosed patients.